| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825449 | Clinical Therapeutics | 2013 | 13 Pages |
Abstract
The findings from the present study suggest that HPβCD-diclofenac does not have a dose-dependent effect in the in vitro hERG assay system and does not produce proarrhythmic QTc prolongation in vivo. ClinicalTrials.gov identifier: NCT01812538.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Daniel B. MD, Tara BA, Annie MSc, Craig R. MD, Douglas A. MBA, Eric MD, Donna MS, Peter G. PhD, Curtis MD, MPH,